Georgian phages funded by Europe
GEORGIAN PHAGES ARE FUNDED BY EUROPE TO PRODUCE PHAGES THAT MEET EUROPEAN MEDICAL STANDARDS.
BioChimpharm: Georgian phage production company
BioChimpharm is a company specialized in manufacturing medicines and health products using biological raw materials. Through the use of biochemistry and biotechnology techniques, it develops innovative drugs that meet patients’ needs. The company focuses particularly on researching and developing new solutions for chronic and rare diseases. In close collaboration with healthcare professionals, BioChimpharm ensures the safety and effectiveness of its products. At the same time, it is committed to producing high-quality medicines to improve patients’ lives, thus contributing to the health and well-being of society.
BioChimPharm is a Georgian biopharmaceutical company specializing in research, development, production, and marketing of sustainable alternatives to antibiotics. It harnesses bacteriophages to create innovative products. With over 80 years of expertise in research, development, and production of antibiotic alternatives, BioChimPharm possesses unique technological know-how. It has obtained ISO 9001-2015 certification, along with the registration of 15 products and two international patents. With over 50 employees, the company currently exports its products to eight countries outside Georgia. It is a legally authorized pharmaceutical manufacturer and exports its products to regional and international markets thanks to regulatory authorizations. Its production facilities and research and development laboratories are located in Tbilisi, Georgia, in a historical bacteriophage production facility dating back to 1934.
BioChimPharm offers a range of products for the treatment and prevention of diseases caused by pathogenic bacteria, primarily in the human and animal health sectors. The company manufactures over-the-counter medicines and dietary supplements. Its laboratory’s mission is to combat antibiotic resistance by eliminating the irrational use of these drugs worldwide. With over 80 years of accumulated experience and the commitment of multiple generations, BioChimPharm provides a revolutionary technology on a global scale. The use of bacteriophages in treatment, known as “phagotherapy,” is a promising approach to combating infections. To learn more about how phagotherapy works, click on the following link: “Phage therapy Treatment.”
Georgian phages from BioChimPharm are funded by Europe and the United Nations.
The frequent use of antibiotics in poultry farming increases health risks for consumers. The innovative products from BioChimPharm serve as an alternative to veterinary antibiotics. With the assistance of the European Union, the company will be able to further develop its product, increase production, and comply with EU standards.
The European Agricultural Fund for Rural Development and the United Nations Food and Agriculture Organization have granted $150,000 to BioChimpharm. The objective is to develop an antimicrobial veterinary solution based on bacteriophages, aiming to reduce the use of antibiotics in livestock. Consumption of such animals has an impact on humans. The funding will support the production of “PowerPhage,” a natural antimicrobial veterinary solution based on bacteriophages. This solution will help reduce antibiotic use in meat production, especially in poultry farming. BioChimPharm aims to increase PowerPhage production by 300%. This grant enables the development and implementation of European standards and modernization of the production line. The funding from the EU and the United Nations Food and Agriculture Organization is part of a total investment of $1,000,000 raised by the company.
To learn more, click on the following link: : Georgian biotech company to increase production of sustainable veterinary antibiotic alternative with EU and FAO support
European Program for Agriculture and Rural Development
Structural and systemic challenges still limit rural development in Georgia. Therefore, Europe has established the European Neighborhood Program for Agriculture and Rural Development (ENPARD). Between March and December 2020, 132 matching grants totaling 8.5 million GEL (Georgian currency) were awarded. The beneficiaries are mainly Georgian farmers, entrepreneurs, cooperatives, and small and medium-sized enterprises located in rural areas. ENPARD, launched in 2013 with a total budget of 234.5 million euros, aims to provide economic opportunities and reduce poverty in Georgia.
Results achieved by BioChimPharm
BioChimPharm has modernized its historical bacteriophage manufacturing plant with an investment of 17.5 million GEL. The EU, the EBRD (European Bank for Reconstruction and Development), the United Nations, and the Ministry of Economy and Sustainable Development of Georgia have supported this action. This modernization has allowed the company to comply with the EU’s Good Manufacturing Practices (GMP) standards.
As a result, BioChimPharm is increasing its production capacity and expanding its export area. The company aims to make phages available to millions of patients worldwide, complying with internationally recognized manufacturing standards. It is undertaking the modernization of its manufacturing plant, high-tech infrastructure, and production lines. Moreover, this will enable more effective combating of resistant infections and contribute to overcoming the global threat of antibiotic resistance.